Please login to the form below

Not currently logged in
Email:
Password:

Takeda mulls bid for Irish biopharma Shire

The Japanese pharma firm must make a formal offer by 25 April

Takeda

Takeda, Japan’s largest pharmaceutical company by sales, has announced that it’s considering a possible takeover deal for Shire, a biopharma focused on rare diseases.

The news sparked a 25% surge in Shire’s shares during yesterday morning’s trading however according to Takeda, the consideration of such an offer is at a ‘preliminary’ and exploratory’ stage, with no actual approach made to the board of Shire.

In a press release announced earlier today, Takeda said a “potential transaction with Shire presents an opportunity to strengthen the company’s core therapeutic areas of oncology, gastrointestinal and neuroscience”.

It also added that the deal could build on Takeda’s “current strong momentum”, and could create a “truly global, value-based Japanese biopharmaceutical leader”.

Takeda, which has until 25 April to make a formal offer, isn’t the only company that has seen potential with Shire, as it was recently tipped as the next big pharma takeover after AbbVie’s failed takeover bid in 2014.

That particular deal, which saw AbbVie offer $55bn for the biopharma, came to a halt after the US introduced new measures to discourage tax inversion deals.

Article by
Gemma Jones

29th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics